Estimating future hepatitis C morbidity, mortality, and costs in the United States.

By John B. Wong, G. Mcquillan, J. Mchutchison, T. Poynard. American Journal of Public Health, 2000

612 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 (2006, background): “Furthermore, the stabilization of HCV prevalence will not prevent the increase in cirrhosis and liver cancer that is projected to result from HCV infections acquired in previous decades (11, 12, 28).”
The global burden of hepatitis C (2009, background): “antiviral treatment) are estimated to be in the range of US$24 000–39 000 lifetime disease costs (23, 28, 34).”
The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007 (2012, background): “The health and economic burden from this coming wave of health care needs will be large and, as these data show, will disproportionately affect persons aged 45 to 64 years (6, 18).”